ECOR
electroCoreFNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
Current thesis
ECOR has real commercial traction: 2025 revenue reached $32.0 million, gross margin was 87%, U.S. prescription sales remained strong, and wellness revenue nearly doubled, so a clean 2026 execution year could rerate a stock valued at only about 1.2x trailing sales [#8-K-2026-03-19].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +23.0.
What can break
Going-concern and future capital-raise risk
Momentum
18
Value
37
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $10.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $19.57
Why
Momentum18 · Δ7d -59.2
Value37 · Δ7d -0.0
Sentiment53 · Δ7d +23.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
18
26% active weight
Current posture
7d trendImproving
Δ7d
-59.2
Δ21d
-69.8
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
53
34% active weight
Current posture
7d trendImproving
Δ7d
+23.0
Δ21d
+19.8
Why this grade
Composite grade F. Momentum 18.4 / Value 36.5 / Sentiment 52.9
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$57.39M
Beta
0.48
Shares Out
9.02M
P/E (TTM) · Derived
-3.9
P/S (TTM)
1.27
P/FCF (TTM) · Derived
-7.91
Rev YoY
+42.6%
EPS YoY
+26.6%
Gross Margin
+85.6%
Op Margin
-44.5%
Net Debt
-$2.21M
Current Ratio
1.02
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology